<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029675</url>
  </required_header>
  <id_info>
    <org_study_id>Faculty of Pharmacy_AinShamsU</org_study_id>
    <nct_id>NCT04029675</nct_id>
  </id_info>
  <brief_title>High Dose of Vitamin C on Mechanically Ventilated Septic Patients in Intensive Care Unit</brief_title>
  <official_title>The Effect of High Dose of Vitamin C on the Clinical Outcome of Mechanically Ventilated Patients Following Sepsis in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Randomized clinical trial study will be carried out in intensive care unit in
      Ain Shams University Hospitals on 40 forty septic patients admitted to ICU and mechanically
      ventilated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out in intensive care unit in Ain Shams University Hospitals ,
      Cairo,Egypt on 40 patients admitted to ICU that are septic patients and mechanically
      ventilated which will be recruited into the study . After approval from ethical committee, an
      informed consent will be obtained from relatives of all patients. All data of patients will
      be confidential with secret codes and private file for each patient. Each patient's relative
      will receive an explanation for the purpose of the study. The study design will be
      prospective , randomized clinical trial.

      Methodology:

      All patients will be subjected to:

        1. Complete history taking.

        2. Full clinical examination

        3. Evaluation and monitoring of(pulse oximetry , ECG, NIBP, temperature)

        4. CBC , Blood gas (for determination of (PaO2/FiO2), Blood cultures,serum Creatinine and
           total bilirubin were recorded daily for the first 7 days.

        5. Severity scores by calculating Acute physiology and chronic health evaluation (APACHE
           II)score
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded ,Prospective, Randomized clinical trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Ventilator -Associated Pneumonia ( VAP)</measure>
    <time_frame>within 28 days</time_frame>
    <description>Ventilator-associated pneumonia (VAP)is defined as pneumonia that occurs 48-72 hours or thereafter following endotracheal intubation, characterized by the presence of a new progressive infiltrate, signs of a systemic infection (fever, altered white blood cells count), changes in sputum characteristics, and detection of a causative agent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Vitamin C level after administration of study drug</measure>
    <time_frame>within 7 days of administered of vitamin C</time_frame>
    <description>Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in SOFA score</measure>
    <time_frame>within 7 days of administered of vitamin C</time_frame>
    <description>SOFA (Sepsis -related Organ Failure assessment) score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day Mortality rate</measure>
    <time_frame>average 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in intensive care unit</measure>
    <time_frame>through the study completion, average 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Glutathione Peroxidase enzyme (GPX) activity</measure>
    <time_frame>within 7 days of administered of vitamin C</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of vasopressor support</measure>
    <time_frame>Average28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days (28-days Cumulative )</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ventilator Associated Pneumonia ( VAP)</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Study Group ( High dose vitamin C group )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>They will receive 1.5 gm intravenous (IV) Vitamin C in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes every 6 hours daily for 4 days or until ICU discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group (Daily requirements vitamin C Group )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive standard daily requirements of Vitamin C intravenously which is 75-90 mg in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes daily for 4 days or until ICU discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function</description>
    <arm_group_label>Control Group (Daily requirements vitamin C Group )</arm_group_label>
    <arm_group_label>Study Group ( High dose vitamin C group )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Age from age≥18 years

          -  Septic patient admitted to ICU and mechanically ventilated diagnosed by sepsis
             criteria proposed by the American College of Chest Physicians/Society of Critical Care
             Medicine

          -  Expected to survive and remain in the ICU for at least 96 hours after study entry

        Exclusion Criteria:

          -  Age&lt;18 years

          -  Pregnant females

          -  Patients with history of aspiration before intubation

          -  Respiratory distress syndrome

          -  Ischemic reperfusion injury

          -  Cancer as the cause of SIRS or sepsis

          -  Chronic kidney diseases

          -  Ongoing shock

          -  Allergy from interventional drug on the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara M. Shahen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim E. Mamdoh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <state>EL Abbasia</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Annane D, Aegerter P, Jars-Guincestre MC, Guidet B; CUB-Réa Network. Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med. 2003 Jul 15;168(2):165-72.</citation>
    <PMID>12851245</PMID>
  </reference>
  <reference>
    <citation>Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 Apr 17;348(16):1546-54.</citation>
    <PMID>12700374</PMID>
  </reference>
  <reference>
    <citation>Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL Jr, Platt R; Academic Medical Center Consortium Sepsis Project Working Group. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997 Jul 16;278(3):234-40.</citation>
    <PMID>9218672</PMID>
  </reference>
  <reference>
    <citation>Tanriover MD, Guven GS, Sen D, Unal S, Uzun O. Epidemiology and outcome of sepsis in a tertiary-care hospital in a developing country. Epidemiol Infect. 2006 Apr;134(2):315-22.</citation>
    <PMID>16490136</PMID>
  </reference>
  <reference>
    <citation>Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000 Jan;181(1):176-80.</citation>
    <PMID>10608764</PMID>
  </reference>
  <reference>
    <citation>CavaillonJ-M.Pathophysiological role of pro-and anti-inflammatory cytokines in sepsis .Sepsis.1998;2(2):127-40.</citation>
  </reference>
  <reference>
    <citation>Kurt AN, Aygun AD, Godekmerdan A, Kurt A, Dogan Y, Yilmaz E. Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis. Mediators Inflamm. 2007;2007:31397. doi: 10.1155/2007/31397.</citation>
    <PMID>18274637</PMID>
  </reference>
  <reference>
    <citation>Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine. 2005 Feb 21;29(4):169-75. Epub 2004 Dec 8.</citation>
    <PMID>15652449</PMID>
  </reference>
  <reference>
    <citation>Manzanares W, Biestro A, Torre MH, Galusso F, Facchin G, Hardy G. High-dose selenium reduces ventilator-associated pneumonia and illness severity in critically ill patients with systemic inflammation. Intensive Care Med. 2011 Jul;37(7):1120-7. doi: 10.1007/s00134-011-2212-6. Epub 2011 Mar 29.</citation>
    <PMID>21445641</PMID>
  </reference>
  <reference>
    <citation>Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest. 2000 Apr;117(4 Suppl 2):177S-181S. Review.</citation>
    <PMID>10816031</PMID>
  </reference>
  <reference>
    <citation>American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416.</citation>
    <PMID>15699079</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, Brun-Buisson C. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998 Sep 15;129(6):433-40.</citation>
    <PMID>9735080</PMID>
  </reference>
  <reference>
    <citation>Leroy O, Sanders V, Girardie P, Devos P, Yazdanpanah Y, Georges H, Beaucaire G. Mortality due to ventilator-associated pneumonia: impact of medical versus surgical ICU admittance status. J Crit Care. 2001 Sep;16(3):90-7.</citation>
    <PMID>11689764</PMID>
  </reference>
  <reference>
    <citation>Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Abroug F, Palizas F, González M, D'Empaire G, Apezteguía C, Esteban A; Internacional Mechanical Ventilation Study Group. Incidence, risk factors, and outcome of ventilator-associated pneumonia. J Crit Care. 2006 Mar;21(1):56-65.</citation>
    <PMID>16616625</PMID>
  </reference>
  <reference>
    <citation>Visser J, Labadarios D, Blaauw R. Micronutrient supplementation for critically ill adults: a systematic review and meta-analysis. Nutrition. 2011 Jul-Aug;27(7-8):745-58. doi: 10.1016/j.nut.2010.12.009. Review.</citation>
    <PMID>21679878</PMID>
  </reference>
  <reference>
    <citation>Sorice A, Guerriero E, Capone F, Colonna G, Castello G, Costantini S. Ascorbic acid: its role in immune system and chronic inflammation diseases. Mini Rev Med Chem. 2014 May;14(5):444-52. Review.</citation>
    <PMID>24766384</PMID>
  </reference>
  <reference>
    <citation>Fowler AA 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S; Medical Respiratory Intensive Care Unit Nursing, Fisher BJ, Natarajan R. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014 Jan 31;12:32. doi: 10.1186/1479-5876-12-32.</citation>
    <PMID>24484547</PMID>
  </reference>
  <reference>
    <citation>Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimazaki S. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg. 2000 Mar;135(3):326-31.</citation>
    <PMID>10722036</PMID>
  </reference>
  <reference>
    <citation>Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W, Lawson TC, Sauberlich HE. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res. 2003 Feb;109(2):144-8.</citation>
    <PMID>12643856</PMID>
  </reference>
  <reference>
    <citation>- de GroothHJ,ChooWP,Spoelstra-deMan AMetal.Pharmacokinetics off our high- dose regimens of intravenousVitamin C in critically ill patients[Abstract]. IntensiveCareMed2016</citation>
  </reference>
  <reference>
    <citation>Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004 Apr 6;140(7):533-7.</citation>
    <PMID>15068981</PMID>
  </reference>
  <reference>
    <citation>Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg. 2002 Dec;236(6):814-22.</citation>
    <PMID>12454520</PMID>
  </reference>
  <reference>
    <citation>Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose Ascorbic acid on vasopressor's requirement in septic shock. J Res Pharm Pract. 2016 Apr-Jun;5(2):94-100. doi: 10.4103/2279-042X.179569.</citation>
    <PMID>27162802</PMID>
  </reference>
  <reference>
    <citation>Ascorbic Acid Injection.TheTorranceCompany,2015.</citation>
  </reference>
  <reference>
    <citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. Review.</citation>
    <PMID>1303622</PMID>
  </reference>
  <reference>
    <citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.</citation>
    <PMID>3928249</PMID>
  </reference>
  <results_reference>
    <citation>Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10.</citation>
    <PMID>11445675</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Wessam Adel El Sayed Abdel Aziz El Driny</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>Mechanically ventilation</keyword>
  <keyword>VAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data that to be shared are age &amp; gender of the participants</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

